cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

Contributed by: Business Wire

Logo

Tags

Other Health

Research

Pharmaceutical

Philanthropy

Genetics

Clinical Trials

Science

Neurology

Other Philanthropy

FDA

Other Science

Health

CORRECTION

More Like This

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

AMRA's muscle biomarkers - Research study explore changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI)

Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals With DMD

New documentary highlights pioneering scientific research into new targets for treatment of motor neuron disease

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

All Digital Mobility Outcomes developed by the Mobilise-D consortium will be accessible through the Empatica Health Monitoring Platform (Photo: Business Wire)

Empatica Announces Integration of Mobilise-D Mobility Outcomes, Advancing Toward Unified Solution for Clinical Professionals